TTY Biopharm Company Limited (TPEX:4105)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
83.70
-0.40 (-0.48%)
At close: Feb 11, 2026

TTY Biopharm Company Balance Sheet

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
2,7132,7732,6212,3572,2222,224
Short-Term Investments
88.88309.02195.54326.86372.65342.4
Cash & Short-Term Investments
2,8023,0822,8172,6842,5952,566
Cash Growth
-2.80%9.41%4.93%3.44%1.12%-11.66%
Accounts Receivable
1,7161,3541,3441,2271,1381,033
Other Receivables
20.323.1828.8129.6813.6216.48
Receivables
1,7361,3771,3731,2571,1511,050
Inventory
1,4171,2701,0961,039955.011,111
Prepaid Expenses
74.9157.9179.0249.8946.9664.15
Other Current Assets
261.066.676.365.371.158.01
Total Current Assets
6,2915,7935,3705,0354,7494,799
Property, Plant & Equipment
2,2212,2462,2872,4332,5192,585
Long-Term Investments
2,1281,9451,5781,4961,4321,458
Goodwill
247.9247.9----
Other Intangible Assets
163.05123.44164.01250.75124.9132.9
Long-Term Deferred Tax Assets
58.5158.5248.7147.163.7261.8
Other Long-Term Assets
436.08448.25426.94337.89407.19324.72
Total Assets
11,54510,8639,8759,6019,2969,361
Accounts Payable
312.73326.16294.66289.4187.27159.44
Short-Term Debt
1,5001,2001,4501,3701,7111,715
Current Portion of Long-Term Debt
400400-418.85407.9116.54
Current Portion of Leases
6.850.935.863.927.62-
Current Income Taxes Payable
211.61228.8156.97149.52150.39110.13
Current Unearned Revenue
33.7734.3414.2333.1339.7716.29
Other Current Liabilities
663.72672.18662.02652.62547.55531.2
Total Current Liabilities
3,1292,8622,5842,9173,0522,549
Long-Term Debt
1001004009.64.15412.05
Long-Term Leases
7.3710.23.053.0414.16-
Pension & Post-Retirement Benefits
17.2117.5427.440.8152.645.5
Long-Term Deferred Tax Liabilities
359.24359.24318.75305.44260.52271.83
Other Long-Term Liabilities
269.282.4435.8391.03146.234.7
Total Liabilities
3,8823,3523,3693,3673,5293,283
Common Stock
2,4872,4872,4872,4872,4872,487
Additional Paid-In Capital
317.56317.04316.62312.18311.88338
Retained Earnings
4,1003,8883,1822,9252,5682,759
Comprehensive Income & Other
-42.158.69-43.79-64.78-198.07-133.71
Total Common Equity
6,8626,7505,9415,6585,1685,450
Minority Interest
801.33760.49564.8574.86599.38628.3
Shareholders' Equity
7,6637,5116,5066,2335,7676,078
Total Liabilities & Equity
11,54510,8639,8759,6019,2969,361
Total Debt
2,0141,7111,8591,8052,1452,144
Net Cash (Debt)
787.911,371957.65878.78450422.47
Net Cash Growth
38.08%43.11%8.97%95.28%6.52%-56.51%
Net Cash Per Share
3.165.503.843.531.811.70
Filing Date Shares Outstanding
248.65248.65248.65248.65248.65248.65
Total Common Shares Outstanding
248.65248.65248.65248.65248.65248.65
Working Capital
3,1622,9312,7872,1181,6982,250
Book Value Per Share
27.6027.1523.8922.7620.7821.92
Tangible Book Value
6,4516,3795,7775,4085,0435,317
Tangible Book Value Per Share
25.9425.6523.2321.7520.2821.38
Land
902.9902.9902.9902.9902.9902.9
Buildings
1,4921,4791,4611,4321,4201,311
Machinery
1,4371,4461,4321,4181,3591,234
Construction In Progress
75.420.598.9577.0995323.33
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.